Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) EBITDA Margin (2021 - 2025)

Aligos Therapeutics filings provide 5 years of EBITDA Margin readings, the most recent being 11756.21% for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 926300.0% to 11756.21% in Q4 2025 year-over-year; TTM through Dec 2025 was 1105.95%, a 97661.0% increase, with the full-year FY2025 number at 1105.95%, up 253030.0% from a year prior.
  • EBITDA Margin hit 11756.21% in Q4 2025 for Aligos Therapeutics, down from 4251.28% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 13853.38% in Q1 2025 to a low of 16326.43% in Q1 2023.
  • Median EBITDA Margin over the past 5 years was 1789.08% (2021), compared with a mean of 2785.44%.
  • Biggest five-year swings in EBITDA Margin: crashed -1493152bps in 2023 and later soared 1888681bps in 2025.
  • Aligos Therapeutics' EBITDA Margin stood at 10085.01% in 2021, then surged by 98bps to 155.63% in 2022, then tumbled by -791bps to 1385.96% in 2023, then tumbled by -80bps to 2493.21% in 2024, then crashed by -372bps to 11756.21% in 2025.
  • The last three reported values for EBITDA Margin were 11756.21% (Q4 2025), 4251.28% (Q3 2025), and 1646.63% (Q2 2025) per Business Quant data.